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Teaser (25-30 words): 
Intravitreally injected antibody-based medicines have revolutionised the treatment of 
retinal disease. Bispecific and dual functional antibodies and therapeutic proteins have 




Antibody-based medicines that target vascular endothelial growth factor 
(VEGF) are administered by intravitreal injection to treat chronic neovascular retinal 
diseases. Much ongoing effort is focused on enhancing therapeutic outcome of these 
medicines. One strategy is the use of dual acting drugs (e.g. bispecific antibodies) to 
simultaneously bind to more than one intraocular biological target. A dual acting 
molecule targeting components within the vitreal cavity could also potentially extend 
vitreous residence time. In this review, the applications of bispecific antibodies within 
the eye are described with consideration to potential targets, applications and suitable 
bispecific formats. 
Introduction 
Intravitreally administered antibody-based medicines targeting vascular 
endothelial growth factor (VEGF) which causes angiogenesis and neovascularisation 
have revolutionised the treatment of neovascular retinal diseases in the 21st century 
[1,2]. Uncontrolled vascularisation and photoreceptor degeneration characterises 
several posterior blinding conditions including wet age-related macular degeneration 
(wet-AMD), diabetic retinopathy (DR) and diabetic macular edema (DME) [3]. VEGF 
is not the only potential target for neovascularisation that may be used to treat chronic 
intraocular blinding disease [4]. Inflammation is also involved in causing blinding 
disease (e.g. posterior uveitis) [5]. Dual targeting protein-based therapeutics such as 
bispecific antibodies (bsAbs) that are capable of interacting with two target epitopes 
simultaneously [6,7] have the potential to increase the efficacy of intraocular 
medicines. 
The concept of bsAbs has long been known [8] and is envisaged to exploit 
spatial temporal relationships that are not possible by using a combination or mixture 
of antibodies [9]. To date, clinical realisation has been achieved in oncology.  
Blinatumomab was approved in 2015 to treat acute lymphoblastic leukaemia and 
emicizumab was approved in 2018 to treat haemophilia A [10]. Catumaxomab was 
approved, but has now been withdrawn for commercial reasons. Blinatumomab is a 
bispecific T-cell engager (BiTe) molecule comprised of two antibody single chain 
variable fragments (scFvs) in a molecule with an overall molecular weight of 
approximately 55 kDa. One fragment of blinatumomab binds to CD19 on a malignant 
B-cell and the other fragment binds to CD3 on a T-cell to redirect and elicit a cytotoxic 
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response [11,12]. Emicizumab is a full IgG antibody that binds to blood factors IXa and 
X to allow the coagulation cascade to continue in the absence of sufficient amounts of 
factor VIII [13]. 
Drug combination versus dual acting molecule 
Drug combination strategies are widely used in medicine, e.g. oncology, and 
infection [14]. Intravitreal injections are invasive and carry some risk, so intraocular 
combination strategies would probably need to be formulated as fixed dose 
combinations to minimise the number of intravitreal injections. Disadvantages of fixed 
dose combinations include a lack of dosing flexibility and difficulties to identify adverse 
reactions. The volume of an intravitreal injection is 50 𝜇L, which is a very small volume 
for a combination of protein-based drugs at sufficient individual doses while minimising 
risks of protein misfolding and aggregation. In spite of these limitations, as described 
below, combinations have been evaluated, but have yet not progressed to clinical 
registration  [14–18].  
The key challenge in developing intraocular medicines is to ensure there is no 
ocular toxicity [19–22]. The eye is susceptible to inflammation which can be caused 
by immunogenicity to the therapeutic protein and possible protein aggregation.  The 
production of anti-drug antibodies (ADAs) and inflammatory responses [19,23] are 
damaging and sight-threatening and must be avoided since intraocular tissues are 
delicate and non-regenerative. It is known that the eye can be susceptible to 
endophthalmitis following injections [24] Proteins that are modified, for example by 
PEGylation, must be manufactured to the highest standard as evidenced by the recent 
regulatory failure and withdrawals of Abicipar pegol [25]. The anti-VEGF PEGylated 
aptamer, pegaptanib sodium appeared to be well tolerated [26] although its use 
decreased after the clinical introduction of ranibizumab and aflibercept. Ocular 
tolerability and safety profiles should be thoroughly assessed. Preclinical and clinical 
studies must carefully designed [21] to minimise and to quickly observe any adverse 
reactions related to the protein of interest [22].  Long term studies moving from 
branded to biosimilar protein therapeutic must also be conducted [27]. In terms of 
bsAbs for development in retinal therapy,  there are ongoing studies in preclinical 
stages with only one bsAb i.e. faricimab targeting VEGF and angiopoietin-2 (ANG-2) 
in full clinical development to treat diabetic macular edema (DME) [28,29] and wet-
AMD [30–32].  
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Considering current anti-VEGF biologics require long-term monthly or 
bimonthly injection, there is also a need to reduce the frequency of intravitreal 
injections to treat chronic intraocular conditions. There has been near exponential 
growth of intravitreal injections since 2007 [33] but the need for repeated intravitreal 
administration is difficult for patients where compliance decreases after the first year 
of treatment [34–36]. Minimising the cumulative number of intravitreal injections is also 
important due to the potential of harmful effects to ocular tissues [37]. Chronic ocular 
hypertension has been associated with repeated intravitreal anti-VEGF injections [38]. 
Dual acting biologics could potentially be developed where one function is to display 
increased affinity to tissue in the posterior cavity to slow clearance from the vitreous 
(affinity targeting) and the other function of the molecule would be to bind to a 
therapeutic target.  
The scope of this review is first to describe intraocular targets that could be 
considered for the development of dual acting biologics and how bispecific molecules 
might be also used to increase duration of action. We also briefly describe different 
bispecific formats. 
Current progress of key intraocular targets  
Targets to inhibit neovascularisation 
VEGF is a proven clinical target for a number of different indications. Since its 
first discovery as an angiogenic factor in late 1980s [39], several medicines have been 
developed as VEGF inhibitors in oncology. To date three antibody-based therapies 
targeting VEGF for intraocular use have been approved, i.e. ranibizumab (Lucentis®), 
aflibercept (Eylea®) and brolucizumab (Beovu®), and 1 non-antibody-based therapy, 
i.e. pegaptanib (Macugen®). Bevacizumab (Avastin®) is also widely used off-label to 
treat intraocular neovascularization. These medicines target epitopes to different 
VEGF subtypes which have been described in several accessible reviews [40–43].  .  
Pegaptanib (Macugen 2004), is a PEGylated ribonucleic acid (RNA) aptamer 
that binds with high affinity to VEGF-A (VEGF165) to its heparin-binding site [44]. 
Binding to the heparin-binding site of VEGF165 does not fully prevent the binding of 
VEGF to VEGFR-2, resulting in poor clinical efficacy compared with the other anti-
VEGF agents. Unlike pegaptanib, ranibizumab (Lucentis, 2006) is an antibody 
antigen-binding fragment (Fab) that binds to VEGF-A to its receptor binding region 
and inhibits VEGF binding to its receptor, VEGFR2 [45]. Aflibercept (Eylea, 2011) is 
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a fragment crystallisable (Fc)-fusion protein that comprises the Fc region of an IgG1 
fused to two copies of the extracellular domain-2 of VEFGR-1 linked to domain three 
of VEGFR-2 [46]. Aflibercept, also called VEGF-trap, has shown a wider binding 
capacity (VEGF-A, VEGF-B and placental growth factor (PIGF)) and higher VEGF 
binding affinity compared to ranibizumab [46]. The patents on ranibizumab and 
aflibercept will expire in the US in 2020 and in Europe in 2022 and 2025 respectively 
[47]. A ranibizumab biosimilar called razumab has been clinically used in India since 
2015. Other biosimilars (FYB 201, Xlucane, PF582, CHS3351, SB11, BCD300) are in 
different stages of clinical trials [47]. Aflibercept biosimilars (ABP 938, ALT-L9, M710, 
CHS-2020) are currently in different phases in clinical trials by different pharmaceutical 
companies in US and South Korean (e.g Amgen, Alteogen, Momenta, Coherus 
Bioscience).  
Bevacizumab (Avastin, 2004) is a full IgG1 that binds to VEGF-A. It is 
formulated and approved for treatment of colorectal cancer and other oncology related 
diseases, but is used off-lable usually after pharmacy fractionation into syringes to 
treat wet-AMD [48]. No difference in visual acuity was observed compared to 
ranibizumab during multi-center randomised controlled clinical trials [49–51]. There 
are biosimilars to bevacizumab that are either approved or in clinical trials, but their 
use is more suitable in oncology rather than ophthalmology.  
Brolucizumab (Beovu, 2019) is a humanised scFv (molecular weight of ~26 
kDa) capable of binding to three isomers of VEGF-A (VEGF110, VEGF121 and VEGF165) 
to prevent their interaction with both VEGFR-1 and VEGFR-2 [52]. An intravitreal 
injection comprises 6 mg of brolucizumab in a single 50 𝜇L dose is approximately 10 
times greater on a molar basis than aflibercept and 20 times greater than ranibizumab. 
The increased molar dose of brolucizumab is thought to allow administration once 
every three months after completion of a dose loading period comprised of three 
monthly injections [52]. Brolucizumab has only recently been approved [53], although 
post marketing concerns over safety have been reported to the American Society of 
Retinal Specialists (ASRS) and case studies [54,55] have subsequently been 
published [56].  
Abicipar pegol is a designed ankyrin repeat protein (DARPin) targeting VEGF-
A which is conjugated to poly(ethylene glycol) (PEG, 20 kDa). DARPins are adapted 
from naturally occurring ankyrin repeat units, and are α-helical scaffold proteins with 
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small molecular weights [57]. A DARPin with seven binding units has a molar mass of 
only 26 kDa, which is less than a Fab such as ranibizumab (~50 kDa). Abicipar has 
an exceptionally high picomolar potency and better stability compared to the approved 
anti-VEGF antibodies in angiogenesis models of the eye [58]. Intraocular inflammation 
was reported during the phase II and III trials [59,60] were thought to be from 
manufacturing impurities [61]. While the FDA has accepted a Biologics License 
Application (BLA) of abicipar [62] the agency did not approve its clinical use (date June 
2020) [63].  
Other anti-VEGF biologics currently in late stage clinical development include 
conbercept, OPT-302 and KSI-301. These biologics are capable of binding to VEGF 
isomers to inhibit binding of VEGF to VEGF-receptors resulting in neutralisation of 
VEGF signalling pathways (e.g angiogenesis and neovascularisation). Conbercept 
and OPT-302 are Fc fusion proteins analogous in their structures to aflibercept. 
Conbercept which has been marketed in China since 2014 and is currently in phase 
III studies in the US, comprises of 2 copies of domain 2 of VEGFR-1 linked to domains 
3 and 4 of VEGFR-2. The Fc region in OPT-302 is fused to two copies of extracellular 
domains 1-3 of VEFGR-3. OPT-302 inhibits VEGF-C and -D and is currently in Phase 
IIb trials for the treatment of neovascular AMD in combination with anti-VEGF-A 
molecules [64,65]. Complete blockade of the VEGF signalling pathway may be 
achieved through inhibition of VEGF-A along with VEGF-C and -D signalling pathways. 
This is suggested to have better results in neovascular regression compared to 
inhibition of single VEGF-A pathway [66]. 
KSI-301 is an anti-VEGF IgG1 antibody that is covalently conjugated to a high 
molecular weight  phosphorycholine biopolymer recently entered phase II clinical trials 
for the treatment of wet-AMD. KSI-301 is designed to block all VEGF-A isomers [67] 
and comprises of IgG1 antibody that covalently conjugated to a high molecular weight. 
The concept is to increase intraocular duration of action by leveraging hydrodynamic 
size and molar dose [68]. KSI-301 appeared to be 3.5 fold greater equivalent molar 
dose than aflibercept [68].  
To augment therapies to inhibit neovascularisation [69], other possible clinical 
targets have emerged (Table 1) including neutralising platelet-derived growth factor-B 
(PDGF-B), PDGF receptor-B (PDGFR-B) [70] and angiopoietin receptors (Tie-2) [71–
73] are also being explored to treat ocular neovascularisation [4]. Targeting vascular 
pathways such as tyrosine kinase receptor 2 or angiopoietin receptors (Tie-2) and 
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platelet-derived growth factors (PDGF and TGF-B) have shown promising results in 
regression of neovascularisation and vessel stabilisation. The Tie-2 receptor, like the 
VEGF receptor, is expressed in the endothelium and plays an important role in 
vascular network progression. Angiopoietin-2 (ANG-2) is a ligand that binds to the Tie-
2 receptor and acts as a pro-angiogenic factor promoting angiogenesis in conjugation 
with VEGF. ANG-2 has also been shown to enhance retinal blood vessel sensitivity to 
the angiogenic effects of VEGF [74]. Nesvacumab is a monoclonal antibody against 
ANG-2 for the treatment of DME.   
PDGF is another growth factor that stimulates blood vessel formation, 
proliferation and angiogenesis, and may contribute to neovascularisation in wet-AMD 
[75]. PDGF binds to PDGFR-A and PDGFR-B which are tyrosine kinase receptors that 
are expressed in vascular smooth muscle cells and pericytes. Pegleranib (Fovista, 
Ophthotech) is a PEGylated aptamer that binds to PDGF-BB to prevent its binding to 
PDGFR-B [76]. Inhibition of PDGF binding to PDGFR-B causes pericytes to be 
stripped from vessels that have been abnormally formed, leading to their regression 
[77]. Another example is the development of rinucumab, an IgG4 monoclonal antibody, 
that targets PDGF-R. These findings suggest that developing biologics inhibiting the 
PDGF or PDGFR pathway might be valid targets for the treatment of ocular 
neovascularisation. 
Drug combinations to target multiple ligands or receptors is successfully widely 
employed in different areas of medicine, e.g oncology and infection. In the case of 
ocular neovascularisation, great efforts have been made to design and formulate drug 
combinations with multiple targets with several examples in phase II trials, but so far, 
these have not been translated into successful phase III trials. For example, targeting 
PDGF and VEGF has been examined with rinucumab (anti-PDGF IgG4 co-formulated 
with aflibercept) and E10030/pegpleranib (Fovista in combination with ranibizumab) in 
phase II and III trials for treatment of wet-AMD respectively [18] but failed to show a 
benefit over anti-VEGF monotherapies.  
Inhibition of Ang-2 in combination with VEGF has also been suggested as a 
potential combination for treating neovascularisation [78]. Two phase II trials have 
been conducted using nesvacumab (anti-ANG-2 antibody) and aflibercept for the 
treatment of wet AMD (ONYX) and DME (RUBY). Results of these trials showed no 
statistical difference between best corrected visual acuity and central subfield 
thickness compared to aflibercept monotherapy [15,16].  
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While the vitreous is an acellular compartment of the eye, there are cellular 
targets that are present in the retinal tissue. Tissue factor (TF) is a surface receptor 
target for coagulation factor VII which initiates the extrinsic coagulation pathway, plays 
an important role in retinal neovascularisation [79]. In a normal healthy eye, TF is not 
expressed by cells but is expressed in response to inflammation by vascular 
endothelial cells, monocytes and macrophages [80]. It has been shown that intravitreal 
injection of anti-TF monoclonal antibody results in reduction of CNV in a mouse model. 
Based on this finding, inhibition of TF was reported as a potential therapeutic target to 
treat retinal neovascularisation, with the ICON-1 molecule having completed phase II 
trials for treatment of choroidal neovascularisation (CNV)  [81–83]. ICON-1 is an Fc-
fusion protein comprising of two human factor VII domains, conjugated to a human Fc 
fragment which selectively binds to TF destroying pathological vessels [84].  
Integrin is another emerging intraocular target which plays an important role in 
regulating cellular adhesion, kinase signalling pathways, endothelial cell migration, 
apoptosis and VEGFR-2 activation leading to network formation during vascular 
development [85]. Inhibition of integrin is of interest because of its potential to have a 
therapeutic role in inhibiting CNV in AMD patients. In general, integrins are 
transmembrane proteins that bind to extracellular matrix (ECM) proteins such as 
laminin, fibronectin and collagen. Integrin a5b1 is a fibronectin receptor involved in 
endothelial cell migration and proliferation [86]. Volociximab is a monoclonal antibody 
that binds to fibronectin to inhibit its binding to integrin a5b1. A phase I trial assessing 
the safety profile of volociximab was completed in 2012 with positive results [87], 
however, to date no further studies have been undertaken to investigate volociximab 
for the treatment of AMD.  
The bioactive lipid sphingosine-1-phosphate (S1P) was thought to be another 
potential intraocular target [88] for which an anti-S1P monoclonal antibody (iSONEP 
or Sphingomab) was developed by Lpath Inc. S1P is a circulating lipid mediator 
generated from metabolism of cell membranes and is involved in multiple mechanisms 
of action in inflammation and angiogenesis [89]. However, iSONEP failed to progress 
past phase II trials because it did not show any significant improvement in visual acuity 
of patients with wet AMD.  
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Targets to inhibit inflammation  
Intraocular inflammation contributes to many disease pathologies including 
neovascularisation and uveitis. Steroids are used to treat uveitis but their efficacy is 
limited. Biologics to target a specific cell type or pathway are being explored for the 
treatment of autoimmune uveitis. Studies in photoreceptor apoptosis have shown that 
proinflammatory cytokines such as tumour necrosis factor-α (TNF-α) and interleukins 
(IL-6, IL-6R, IL1-β, IL-17A and IL-23) [90] could play an important role in the 
progression of neovascular and inflammatory diseases. While targets to treat 
inflammation have begun to emerge, most investigations have been conducted by 
administering the antibodies parenterally rather than by intraocular injection since 
intravitreal formulations have not yet been developed. Adalimumab is a fully human 
monoclonal antibody against TNF-α that has been approved by the FDA and European 
Medicines Agency (EMA) to treat non-infectious, posterior and pan-uveitis in adults 
and children over 2 years old [5,91].  
Tocilizumab targets the interleukin 6R (IL-6R) and is approved for the treatment 
of rheumatoid arthritis, and is currently in phase II trials for the treatment of refractory 
Behcet’s uveitis. Elevated concentrations of IL-6 has been detected in the vitreous of 
patients with posterior uveitis [92,93]. Safety and efficacy of another anti-IL-6R 
antibody called sarilumab is being evaluated in phase II trials for posterior segment 
non-infectious uveitis. Satralizumab, an anti-IL6R antibody, has recently been 
developed for other inflammatory related disease, neuromyelitis optica spectrum 
disorder as one of a rare neurological brain condition caused by inflammation in optic 
nerve.  
Canakinumab and gevokizumab are two antibodies targeting IL-1β. 
Canakinumab is approved for treatment of two forms of cryopyrin-associated periodic 
syndrome (CAPS), as an intravenous formulation has recently completed (in July 
2020) the phase II trails for Behcet’s associated uveitis. Gevokizumab is being 
developed by the XOMA Corporation, but unfortunately has failed to meet its primary 
endpoint in phase III trials [94] for the treatment of uveitis.  
Other proinflammatory targets such as IL-17 and IL-23 have been shown to 
contribute to the progression of uveitis disease [95] leading to the development of  anti-
IL-17 (secukimumab) and anti-IL-23 (ustekinumab) antibodies. While secukimumab 
failed to progress phase III [96] ustekinumab is currently in phase II trials [97] (Table 
1). Insulin like growth factor (IGF-1R) has also been examined and an anti-IGF-R1 
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antibody, teprotumumab, has been approved to treat thyroid eye disease as muscles 
and fatty tissues behind the eye become inflamed [98].  
The antibodies targeting anti-inflammatory cytokines are given in high does (e.g 
5 mg/kg) because they are systemically administrated by parenteral route. High doses 
are necessary to achieve some biodistribution within the eye. Intravitreal dosage forms 
have not been developed, so safety concerns remain including an increased incidence 
of endophthalmitis. Development of intravitreal dosage forms would better ensure that 
a reproducible dose could be delivered intraocularly. Since intravitreal doses are low 
relative parenteral doses, there would be less systemically associated side effects.  
Dual therapeutic targeting  
Faricimab (represented in Figure 1A) is an IgG antibody with the capability to bind two 
therapeutic targets. Faricimab which comprises one Fab with specificity to VEGF and 
another Fab with specificity to ANG-2, is in phase III trials for the treatment of wet-
AMD [30] and DME [29]. Blocking two soluble targets, dual acting antibodies could 
combine the activities of two pathway-modulating molecules into one for enhanced 
efficacy. Faricimab was developed as researchers began to look beyond anti-VEGF 
monotherapies due to poor response and recurrence of disease [99]. Benest et al. 
[100] found that a reduction in ANG-2 concentration strongly reduced the effect of 
vascular leakage upon administration of VEGF as ANG-2 upregulates the 
neovascularisation effects of VEGF. Faricimab was optimised for use in the eye by 
abolishing its Fc binding interactions with FcγR and FcRn. This was achieved by 
exchanging the amino acids required for Fc related interactions. Phase III Trials 
(YOSEMITE, TENAYA) are underway to compare efficacy and pharmacokinetics of 
faricimab using a 8 weeks dosing interval with aflibercept for both wet-AMD and DME 
treatment [29,78]. Considering the need to avoid ocular toxicity and develop more 
efficacious drugs, as a bispecific faricimab appears to demonstrate a favourable safety 
profile. There were no reports of intraocular inflammation during the phase II 
BOULEVARD trial up to 36 weeks [28]. However, data obtained during the phase III 
clinical trials will provide more detail about the safety profile of faricimab. 
Another example for dual acting antibody with two therapeutic targets is the 
development of a molecule called valpha which was investigated by Korea Advanced 
Institute of Science. Valpha is a Fc-based bispecific molecule that targets VEGF and 
TNF-α [101] It comprises of soluble VEGF and TNF-α receptors, which are fused to a 
 11 
Fc IgG region. A study showed that when compared to two control monospecific (anti-
VEGF aflibercept and anti-TNFα etanercept) therapies, valpha has the potential to 
increase treatment effectiveness due to its dual targeting approach, and a favourable 
pharmacokinetic profile [101]. Valpha has the potential to be a cost-effective strategy 
for the treatment of AMD. However, it appears that no further development has been 
conducted on this molecule since 2011. While the reasons for the lack of development 
have not been publicly disclosed and there is no indication of a lack of efficacy, the 
presence of the Fc region in the bispecific format could lead to ocular or/and systemic 
cytotoxicity, which will be reviewed in following section. The lack of Fc function is 
important because upon clearance from the eye, there will be no Fc mediated recycling 
or effector function which may reduce systemic safety risks.  
Dual action molecules designed for increased duration of action  
There is a recognised need to increase the duration of action of intravitreally 
administered medicines [36,102–104]. There is often reduced compliance by patients 
after the first year of treatment [34,69], especially patients that have not previously 
participated in a clinical trial [35,36]. Strategies to develop complex formulations of 
therapeutic proteins [105–107] have been considered, but these strategies must 
address the challenges to maintain protein stability [108–110] and ocular tolerability 
[19,23]. The Port Delivery System (PDS) is a refillable reservoir for the long-term 
administration of ranibizumab that is currently undergoing Phase III trials [111,112]. 
The PDS is implanted in the sclera with an extra scleral flange with a self-sealing 
septum designed to allow access to the reservoir to remove and replenish drug in a 
clinical setting using aseptic technique. While this strategy avoids the need of an 
intravitreal injection, the implantation of the PDS must be accounted for when 
considering the range of possible adverse reactions [113].  
Another strategy to potentially increase the residence time of a therapeutic 
protein in the vitreous is for the protein to associate or bind to a tissue component 
within the vitreous cavity. As a large molecular weight molecule possessing charge, a 
therapeutic protein generally clears via aqueous outflow after diffusing from the 
vitreous into the anterior chamber where convective flow clears into the conjunctiva 
[114,115].  If there is an absence of interactions with ocular tissue in the posterior 
cavity, the clearance of biotherapeutics is primarily dominated by molecular size 
because molecules diffuse from the viscous vitreous gel  [106,114–116]. Charge and 
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hydrophobicity characteristics of therapeutic proteins appear to make little contribution 
to the elimination time from the vitreous compared to the influence of the size of the 
therapeutic protein in solution (i.e. hydrodynamic radius) [116].  The vitreous often 
becomes less viscous as we age, so the diffusion times, and thus clearance times can 
show considerable interpatient variation [104,117–119].  
Affinity drug delivery strategies have attracted interest [120,121] and transient 
interactions between a therapeutic protein and an endogeneous intraocular target 
[122]  can in principal be used to reduce clearance times from the vitreous cavity.  After 
a loading dose has been administered, a therapeutically beneficial maintenance dose 
at low concentration can in principle be achieved by an affinity strategy. 
Extending vitreous residence time by affinity can either involve binding to an 
endogenous target in the posterior cavity (e.g. hyaluronic acid (HA), collagen) (Table 
2) or possibly to an exogenously administered target (e.g. binding to hydrogel or 
implant) [123]. Some relevant tissue component binding constants have been reported 
[124] and the amounts of possible vitreous targets have also been described [122].  
Binding to a target in the vitreous must not cause any ocular toxicity or 
interference with vision. Also, to ensure rapid systemic clearance after the drug exits 
the eye, the selected anchoring target in the vitreous should ideally not be present in 
the blood compartment. For example, small amounts of albumin have been found in 
the healthy vitreous and the amount of albumin may be higher in some disease 
conditions such as diabetic retinopathy [125]. The challenge is that albumin in the 
blood compartment would then act to extend the circulation time of the drug after 
clearing from the eye. While targeting albumin in circulation is well known and is a 
clinically proven strategy [126–128], utilising albumin in the eye may be limited if the 
drug is also not required systemically after clearing from the eye.   
Researchers from Novartis described a bispecific molecule comprised of an 
anti-VEGF Fab fused with the HA-binding component derived from hyaladherin [122]. 
Results showed that HA binding anti-VEGF adducts displayed ~3-4 fold longer half 
lives in rabbit and monkey eyes than non-HA binding controls. Inhibition of VEGF-
induced vascular leak was also 3-4 times longer in animal models with the HA binding 
bispecifics.  
Another example has been described by Roche [129] that reports the 
preparation of a recombinant fusion protein (peptide linker) with the first binding site 
(Fab or scFv) has therapeutic action targeting VEGF, and the second binding site 
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specifically binds to type II collagen (scFv) [129]. The bispecific molecule increased 
diffusion time by 2.7 times in phosphate buffered saline containing collagen and 3.2 
times in vitreous fluid compared to the therapeutic Fab without the affinity binding 
moiety.  
Targeting heparan sulphate proteoglycans (HSPGs) has also been suggested 
as another affinity target to prepare a dual acting molecule [130]. HSPGs are cell 
surface glycoproteins of heparan sulphate found on retinal pigment epithelial (RPE) 
cell surface and also in the ECM and basement membrane. Heparin binding domains 
(HBDs) are the ligands binding to HSPGs to regulate cell activities. Fusion of HBDs to 
the aflibercept in “sticky-trap” molecule, resulted in prolonged drug retention within the 
vitreous for 12 days longer than aflibercept [131].  
The concept of affinity targeting in the eye has also been extensively described 
with melanin, but mostly for low molecular weight molecules. Melanin is the most 
common light-absorbing pigment and is located in melanosome vesicles within the 
retinal pigment epithelium (RPE) cells [132] and approximately 6-8 mg of melanin is 
present in the ocular tissues [133]. Urtti and coworkers have reported extensively on 
drug-melanin binding [104,134–139]; and have recently established a correlation 
between in vitro binding and in vivo pharmacokinetics [140]. Drugs can bind to melanin 
altering its pharmacologic and pharmacokinetic profiles [141] by forming a reservoir to 
prolong residence time [142,143]. Intravitreal administered low molecular weight 
molecules that bind to melanin have been reported [138,144,145] namely β-blockers, 
celecoxib and chloroquine. Melanin binding is more pronounced with lipophilic drugs 
(e.g. beta-blockers) [146–148].  
The duration of action of a drug may also be extended by developing an 
exogenously administered binding target (or anchor). Shoichet and coworkers have 
explored the affinity between a protein and a hydrogel [121,123,149–152]. In one study 
by Delpace et al[123], ciliary neurotrophic factor (CNTF) was expressed as a model 
protein with neuroprotective effect on the retina and then fused with Src homology 3 
(SH3) domain. The CNTF-SH3 molecule was then formulated with a hydrogel system 
(hyaluronic acid and methylcellulose). The hydrogel composition was modified with an 
SH3 binding peptide allowing reversible binding of the fusion protein (CNTF-SH3) to 
the gel matrix [123]. Intravitreal injection to the retina, the  In vivo activity was similar 
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to that of commercial CNTF; however, there was a lack of prolonged effect for CNTF-
SH3, due to insufficient protein being present at 7 days[123]. 
Bispecific molecular motifs include IgG and non-IgG formats  
The IgG format (e.g faricimab Figure 1A) is not the only molecular format that 
is being examined for use as a bispecific, dual functional therapeutic protein for 
intraocular use. Fc-fusion (e.g. aflibercept) and Fab (e.g. ranibizumab) possess 
elements of the IgG format. Non-IgG formats that have already been referred to are 
brolucizumab, which is a scFv and abicipar which is a DARPin. These and other non-
IgG formats [153–155] along with other molecules described in the patent literature  
[156,157] may also have potential intraocular applications. Other non-IgG formats 
(such as nanobodies, Diabodies, BiTEs and DARTs) that have been developed for 
use in oncology, may not be ideal for systemic use due to suboptimal clearance rates 
from the blood compartment. These may potentially emerge for intraocular use.     
As with antibody-based medicines that are considered to have be related to the 
IgG motif (e.g. IgG, Fab, Fc-fusion), the non-IgG formats are protein-based molecules 
that are large sized (> 10 kDa), charged molecules in solution. Although the Fc function 
in an IgG molecule can be disabled by molecular engineering (e.g. faricimab), the non-
IgG formats do not have an Fc region.   
A bispecific DARPin targeting VEGF and PDGF is currently in pre-clinical 
development for ocular diseases [158] and has not yet entered clinical trials. In this 
molecule, two different DARPins are linked via peptide linkage. The structure of a 
bispecific DARPin is shown in Figure 1B. Nanobodies are derived from camelids 
including camels, llamas and alpacas [159]. They are comprised of heavy chain 
variable regions and have molecular weights as low as 13 kDa. Nanobodies share a 
number of advantages with DARPins that may be important for intraocular used 
including high solubility, stability and small molecular size [159]. Bispecific nanobodies 
can be synthesised linking two different nanobodies with a shorter linker sequence 
(Figure 1C). Despite these advantages, there are no bispecific nanobodies yet being 
developed for ocular diseases. However, an interesting bispecific nanobody, called BI 
836880, that blocks VEGF and ANG-2 has been described for oncology and is 
currently in phase I clinical trials [160].  
Diabodies, BiTEs and DARTs are other non-IgG formats that can be made into 
bispecific molecules. These formats comprise scFvs linked together by different 
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arrangements. BiTE (bispecific T-cell engager) are non-endogenous molecules 
comprised of two scFvs and have a molecular weight of approximately 50kDa. They 
are manufactured with peptide linking two scFvs derived from different monospecific 
monoclonal antibodies [161], in contrast to diabodies in which the variable fragments 
contain light and heavy chains from the same antibody. A key to the functionality of 
BiTE molecules is a freely rotatable peptide linkage. The freely rotatable linkage 
enables the scFvs to interact with targets on different cell surfaces or while in solution. 
The DART platform comprises two scFvs which contain interchain linkers and covalent 
bonds. This non-endogenous configuration limits the rotation of the antigen binding 
domains in contrast to the free rotatable BiTE [162]. All three formats (diabodies, BiTE 
and DART) have entered clinical development in oncology with the most successful 
(to date) being blinatumomab (Blincyto). Currently these drugs are formulated as 
parenteral dosage forms and are not yet made into high concentration formulation 
[163] required for ocular application. In addition, there are general concerns regarding 
the stability, toxicity, and immunogenicity caused by peptide linker for diabodies and 
BiTE molecules which may pose challenges for intraocular use.  
Other bispecific formats that have shown promising results for ocular 
indications are bispecific aptamers and bispecific F(ab)2. Bispecific aptamers such as 
SOMAmers which target VEGF and PDGF have been made by SomaLogic, Inc 
[164,165]. Bispecific F(ab)2 is another design with the potential benefit of being a 
“human-like” bispecific mimicking a human IgG structure without the Fc (Figure 1D). 
The F(ab)2, could be an interesting format to peruse because of the success of 
ranibizumab for treatment of wet-AMD. The inclusion of two Fabs and the lack of the 
Fc in the F(ab)2 bispecific, could enhance the targeting properties of these molecules 
while maintaining the favourable rapid systemic pharmacokinetic profile of the Fabs 
[166]. 
In a bispecific F(ab)2, two different Fabs can be linked together either by a 
peptide linker or polymer linker. Two Fabs could have dual therapeutic function or 
affinity-based function with one Fab binding to a vitreous specific tissue and the other 
Fab having a therapeutic function. We have recently synthesised a monospecific 
F(ab)2 like format, a Fab-PEG-Fab molecule (FpF) using a recombinant-chemical 
approach. The FpF molecule shows many similarities to an IgG molecule (e.g. solution 
size and binding affinity).  An FpF is synthesised by site-specific conjugation of two 
Fabs using a safe poly (ethylene glycol) (PEG) linking molecule (Figure 2A) [167–
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170]. The Fab interchain disulfides in the FpF mimetics, are stabilised by reannealing 
disulfide bridging conjugation. The presence of PEG reduces the propensity of the 
FpFs to aggregate. The FpFs displayed slower dissociation rate constant (koff) 
compared to the parent IgG, the binding affinity (KD) for FpF appeared to be similar as 
IgG for both VEGF and TNF [167–170]. The anti-TNF FpF displayed comparable 
anti-inflammatory activity as infliximab in an uveitis mouse model [170]. Exploiting 
reduced dissociation rates (koff) of therapeutics may be a viable approach to increase 
efficacy within ocular tissue. We have also prepared Fc-fusion mimetics called RpRs 
(receptor-PEG-receptor) with similar binding properties.  We are currently developing 
the bispecific FpFs (Figure 2B) designed for intraocular applications [171]. 
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Future prospects: As with any therapeutic, target selection is a first critical 
step for the development of dual acting, or bispecific biotherapeutics. Target selection 
is compounded by the need to select two different targets that together will bring 
clinical benefit. Bispecific therapeutics are clinically proven in oncology where they can 
exploit spatial temporal relationships that are not possible using a combination of 
constituent drugs. The use of intravitreally administered drug combinations has been 
limited to date by not meeting efficacy endpoints and may be further limited by 
formulation challenges and regulatory requirements. Challenges with the scale of the 
manufacturing process, characterisation and product stability slow their clinical 
development. Therefore there may be more opportunities than anticipated based 
purely on spatial temporal relationships to develop bispecific biotherapeutics for 
intraocular use. Future development of bispecifics for intraocular applications requires 
that there is no ocular toxicity caused by the therapeutic. All molecular formats will 
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Figure 1 Structures of five bispecific antibodies (IgG and non-IgG formats) for ocular indications: 
(A): A bispecific antibody produced using CrossMAb technology. (B): A bispecific DARPin containing 
two DARPins linked by a peptide linker (adapted from PDB entry 500U). (C): A bispecific nanobody 
molecule, two heavy chain only antibody fragments linked together by a peptide linkage. (D): A 
bispecific F(ab)2 molecule, two Fab regions are linked via a hinge disulphide bond. (E): A bispecific 
aptamer molecule containing two oligonucleotide aptamers linked together via a peptide linkage 






Figure 2 Structures of monospecific and bispecific FpF molecules: 
(A) A monospecific FpF in which two identical Fabs are covalently bound to end of a protein dimerisation 
reagent to form a homodimer. (B) A bispecific FpF in which two different Fabs are covalently bound to 





































Phase III [1,2]  
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Table 2.  Affinity bispecific antibodies in preclinical development for the treatment of ocular neovascu-





Name of drug Format Group/Company 
VEGF + 
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Fab + HA-binding 




trap fused with 
HBDs) 
Michael et al [35] 
VEGF+ 
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Fusion protein 
(scFv fused with 
Fab) 
Roche [36] 
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